GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ivonescimab   Click here for help

GtoPdb Ligand ID: 13396

Synonyms: AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
Approved drug Immunopharmacology Ligand
ivonescimab is an approved drug (China (2024))
Compound class: Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It was designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [5].
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes. China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
11809 ivonescimab
Synonyms Click here for help
AK-112 | AK112 | Idafang® (China) | SMT-112 | SMT112
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1196
Other databases
GtoPdb PubChem SID 496703366
Search PubMed clinical trials ivonescimab
Search PubMed titles ivonescimab
Search PubMed titles/abstracts ivonescimab